NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
CEO Amir Heshmatpour and CMO Thomas Chen purchased 160,016 shares totaling ~$629,000 in open market purchases following NeOnc's August 12, 2026 announcement of positive Phase 2a results for NEO100 (48.9% six-month progression-free survival vs. 20% benchmark, p=0.0047; median overall survival 26.09 months). Heshmatpour alone bought 111,000 shares for ~$418,700 at avg. $3.77/share since the positive results announcement; Chen bought 49,016 shares for ~$210,000. Heshmatpour states he has invested >$1.5M in company shares over the past year.
Why this rating
Insider buying signals confidence, positive Phase 2a data is encouraging for clinical-stage biotech. However, 24-patient uncontrolled trial; $629K is <1% of company market cap; early biotech results frequently fail in larger trials.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.